AssayIndex
WXT cross-section

WXT by compound

WXT records split by compound, with the index-wide comparison for the same compound beside each one. 26 compounds, 301 records. Cells below n=3 print their raw values instead of a median.

26 compounds301 records
CompoundClassReportsWXT median %Index median %Δ (pp)SpecPass %
SemaglutideIncretin5397.9098.89-0.9997.096
BPC-157Tissue-repair3498.6799.16-0.4998.079
PT-141 (Bremelanotide)Melanocortin-receptor2798.6999.38-0.6998.567
L-Glutathione (reduced)Short2498.0799.33-1.2698.521
TirzepatideIncretin2498.5998.55+0.0497.0100
MK-677 (Ibutamoren mesylate)Non-peptide1799.2999.49-0.2098.5100
MOTS-cMetabolic1398.4699.13-0.6798.062
LeuprolideHypothalamic1298.8399.28-0.4598.592
CJC-1295 (no DAC)Growth-hormone1298.6399.09-0.4798.083
GHRP-2Growth-hormone1198.5799.28-0.7299.018
SurvodutideIncretin1097.8798.38-0.5196.5100
5-Amino-1MQNon-peptide998.7199.45-0.7598.089
CJC-1295 with DACGrowth-hormone897.2098.95-1.7597.538
N-Acetyl Semax AmideNeuroactive7 n=798.4099.35-0.9598.543
IGF-1 LR3Growth-hormone6 n=696.9798.28-1.3195.0100
TB-500Tissue-repair5 n=597.8599.53-1.6898.50
Enclomiphene citrateNon-peptide5 n=599.0899.44-0.3698.5100
GHRP-6Growth-hormone5 n=599.0499.54-0.5099.080
SermorelinGrowth-hormone4 n=498.9499.06-0.1298.075
ARA-290Tissue-repair4 n=499.2399.42-0.1998.0100
SemaxNeuroactive4 n=498.6999.46-0.7798.5100
TesamorelinGrowth-hormone2 n=2n<398.2997.050
SelankNeuroactive2 n=2n<399.5999.0100
Melanotan IIMelanocortin-receptor1 n=1n<399.4298.5100
LiraglutideIncretin1 n=1n<399.0097.50
IpamorelinGrowth-hormone1 n=1n<399.4799.0100
96.397.097.698.398.999.6100.2SemaglutideSemaglutide: Q1 97.39, median 97.90, Q3 98.45, n=53n=53BPC-157BPC-157: Q1 98.03, median 98.67, Q3 98.98, n=34n=34PT-141 (Bremelanotide)PT-141 (Bremelanotide): Q1 98.41, median 98.69, Q3 99.03, n=27n=27L-Glutathione (reduce…L-Glutathione (reduce…: Q1 97.88, median 98.07, Q3 98.40, n=24n=24TirzepatideTirzepatide: Q1 98.31, median 98.59, Q3 98.89, n=24n=24MK-677 (Ibutamoren me…MK-677 (Ibutamoren me…: Q1 99.10, median 99.29, Q3 99.59, n=17n=17MOTS-cMOTS-c: Q1 97.84, median 98.46, Q3 98.68, n=13n=13LeuprolideLeuprolide: Q1 98.64, median 98.83, Q3 99.12, n=12n=12CJC-1295 (no DAC)CJC-1295 (no DAC): Q1 98.26, median 98.63, Q3 98.71, n=12outlier 97.52n=12GHRP-2GHRP-2: Q1 98.34, median 98.57, Q3 98.79, n=11outlier 97.35n=11SurvodutideSurvodutide: Q1 97.79, median 97.87, Q3 98.02, n=10outlier 98.51n=105-Amino-1MQ5-Amino-1MQ: Q1 98.27, median 98.71, Q3 98.80, n=9n=9CJC-1295 with DACCJC-1295 with DAC: Q1 97.12, median 97.20, Q3 97.59, n=8n=8N-Acetyl Semax AmideN-Acetyl Semax Amide: Q1 98.27, median 98.40, Q3 98.69, n=7n=7 Purity (% area)
Figure. Distribution per compound where n ≥ 4. Rows are ordered by coverage, not by result.

Which of these lines WXT actually stocks

Coverage here reflects what has been submitted to the index, not what is on the catalogue. WuXi TIDES (WuXi AppTec Testing Division) lists considerably more than the 26 compounds above. Of those 26, 17 have been seen arriving from a domestic warehouse rather than as a cross-border consignment — that is the whole of what the index can say about which lines are held in regional stock, and it is a record of what was submitted, not a stock position. The catalogue and the current stock position are on the supplier's own site.

Browse the WXT catalogue at wuxitides.net →